Literature DB >> 30507725

Does the clinical phenotype of mucolipidosis-IIIγ differ from its αβ counterpart?: supporting facts in a cohort of 18 patients.

Sheela Nampoothiri1, Nursel H Elcioglu2, Suleyman S Koca3, Dhanya Yesodharan1, Chandrababu Kk4, Vinod Krishnan4, Meenakshi Bhat5, Natasha Radhakrishnan6, Mahesh Kappanayil7, Jayesh J Sheth8, Sandra Alves9, Francisca Coutinho9, Michael J Friez10, Richard M Pauli11, Sheila Unger12, Andrea Superti-Furga12, Jules G Leroy10, Sara S Cathey10.   

Abstract

Mucolipidosis-IIIγ (ML-IIIγ) is a recessively inherited slowly progressive skeletal dysplasia caused by mutations in GNPTG. We report the genetic and clinical findings in the largest cohort with ML-IIIγ so far: 18 affected individuals from 12 families including 12 patients from India, five from Turkey, and one from the USA. With consanguinity confirmed in eight of 12 families, molecular characterization showed that all affected patients had homozygous pathogenic GNPTG genotypes, underscoring the rarity of the disorder. Unlike ML-IIIαβ, which present with a broader spectrum of severity, the ML-III γ phenotype is milder, with onset in early school age, but nonetheless thus far considered phenotypically not differentiable from ML-IIIαβ. Evaluation of this cohort has yielded phenotypic findings including hypertrophy of the forearms and restricted supination as clues for ML-IIIγ, facilitating an earlier correct choice of genotype screening. Early identification of this disorder may help in offering a timely intervention for the relief of carpal tunnel syndrome, monitoring and surgery for cardiac valve involvement, and evaluation of the need for joint replacement. As this condition may be confused with rheumatoid arthritis, confirmation of diagnosis will prevent inappropriate use of immunosuppressants and disease-modifying agents.

Entities:  

Mesh:

Year:  2019        PMID: 30507725     DOI: 10.1097/MCD.0000000000000249

Source DB:  PubMed          Journal:  Clin Dysmorphol        ISSN: 0962-8827            Impact factor:   0.816


  3 in total

1.  Clinical Characterization of Mucolipidoses II and III: A Multicenter Study.

Authors:  Taciane Alegra; Fernanda Sperb-Ludwig; Nicole Ruas Guarany; Erlane M Ribeiro; Charles M Lourenço; Chong Ae Kim; Eugênia R Valadares; Marcial Francis Galera; Angelina X Acosta; Dafne Dain Gandelman Horovitz; Ida Vanessa Doederlein Schwartz
Journal:  J Pediatr Genet       Date:  2019-09-24

2.  Clinical, radiological and computational studies on two novel GNPTG variants causing mucolipidosis III gamma phenotypes with varying severity.

Authors:  Mustafa Doğan; Recep Eröz; Kerem Terali; Alper Gezdirici; Semih Bolu
Journal:  Mol Biol Rep       Date:  2021-01-28       Impact factor: 2.316

3.  Pathogenic variants in GNPTAB and GNPTG encoding distinct subunits of GlcNAc-1-phosphotransferase differentially impact bone resorption in patients with mucolipidosis type II and III.

Authors:  Giorgia Di Lorenzo; Lena M Westermann; Timur A Yorgan; Julian Stürznickel; Nataniel F Ludwig; Luise S Ammer; Anke Baranowsky; Shiva Ahmadi; Elham Pourbarkhordariesfandabadi; Sandra R Breyer; Tim N Board; Anne Foster; Jean Mercer; Karen Tylee; Renata Voltolini Velho; Michaela Schweizer; Thomas Renné; Thomas Braulke; Dévora N Randon; Fernanda Sperb-Ludwig; Louise Lapagesse de Camargo Pinto; Carolina Araujo Moreno; Denise P Cavalcanti; Michael Amling; Kerstin Kutsche; Dominic Winter; Nicole M Muschol; Ida V D Schwartz; Tim Rolvien; Tatyana Danyukova; Thorsten Schinke; Sandra Pohl
Journal:  Genet Med       Date:  2021-08-02       Impact factor: 8.822

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.